<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04784299</url>
  </required_header>
  <id_info>
    <org_study_id>LG-HACL029</org_study_id>
    <nct_id>NCT04784299</nct_id>
  </id_info>
  <brief_title>To Evaluate the Performance and Safety of YVOIRE Volume Plus for Improvement of Mid-face Volume</brief_title>
  <official_title>A Randomized, Multicenter, Evaluator-Blinded, Active-Controlled, Parallel-Group Design Investigation to Evaluate Performance and Safety of YVOIRE Volume Plus Versus Restylane Lyft With Lidocaine for Temporary Improvement of Mid-face Volume</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LG Chem</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LG Chem</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Study to Evaluate the Performance and Safety of YVOIRE volume plus for Temporary&#xD;
      Improvement of Mid-face Volume&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Randomized, Multicenter, Evaluator-Blinded, Active-Controlled, Parallel-Group&#xD;
      Design Investigation to Evaluate the Performance and Safety of YVOIRE volume plus versus&#xD;
      Restylane Lyft with Lidocaine for Temporary Improvement of Mid-face Volume.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 22, 2021</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Non-inferiority of YVOIRE volume plus versus Restylane Lyft with Lidocaine</measure>
    <time_frame>24 weeks from baseline</time_frame>
    <description>To demonstrate non-inferiority of YVOIRE volume plus versus Restylane Lyft with Lidocaine in the improvement of mid face volume by comparing the mean change from Baseline in the Mid Face Volume Loss Rating Scale (MFVLRS) at 24 weeks after the final treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Responder rate of YVOIRE volume plus</measure>
    <time_frame>24 weeks from baseline</time_frame>
    <description>To confirm performance of YVOIRE volume plus by the responder rate (defined as at least 1-point improvement from Baseline) at 24 weeks after the final treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Change of Mid Face Volume Loss Rating Scale (MFVLRS)</measure>
    <time_frame>4, 8, 12, 52 weeks from baseline</time_frame>
    <description>To compare the performance of YVOIRE volume plus to Restylane Lyft with Lidocaine based on the MFVLRS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Responder rate of YVOIRE volume plus</measure>
    <time_frame>4, 8, 12, 52 weeks from baseline</time_frame>
    <description>To confirm performance of YVOIRE volume plus by the responder rate (defined as at least 1-point improvement from Baseline) at 24 weeks after the final treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Score of Mid Face Volume Loss Rating Scale (MFVLRS)</measure>
    <time_frame>4, 8, 12, 24, 52 weeks from baseline</time_frame>
    <description>o compare the performance of YVOIRE volume plus to Restylane Lyft with Lidocaine based on the MFVLRS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The mean scores of the GAIS</measure>
    <time_frame>4, 8, 12, 24, 52 weeks from baseline</time_frame>
    <description>To compare the performance of YVOIRE volume plus to Restylane Lyft with Lidocaine based on Global Aesthetic Improvement Scale (GAIS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in mid-face volume</measure>
    <time_frame>24 weeks from baseline</time_frame>
    <description>To compare the performance of YVOIRE volume plus to Restylane Lyft with Lidocaine based on the three dimensional (3-D) photograph measurement</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">105</enrollment>
  <condition>Midface Volume Deficit</condition>
  <arm_group>
    <arm_group_label>YVOIRE volume plus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hyaluronic acid dermal filler</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Restylane Lyft with Lidocaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Hyaluronic acid dermal filler</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>YVOIRE volume plus</intervention_name>
    <description>Hyaluronic acid dermal filler</description>
    <arm_group_label>YVOIRE volume plus</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Restylane Lyft with Lidocaine</intervention_name>
    <description>Hyaluronic acid dermal filler</description>
    <arm_group_label>Restylane Lyft with Lidocaine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female aged between 21 to 75 years (inclusive)&#xD;
&#xD;
          -  2 or 3 on the 5-point MFVLRS (Mid Face Volume Loss Rating Scale)&#xD;
&#xD;
          -  Desire cheek augmentation to correct volume deficit in the midface.&#xD;
&#xD;
          -  Agree to use contraception&#xD;
&#xD;
          -  Sign Informed Consent Form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  have undergone facial plastic surgery, tissue grafting, or tissue augmentation with&#xD;
             silicone, fat, or other permanent, or semi-permanent dermal fillers in the midface&#xD;
             area&#xD;
&#xD;
          -  have undergone temporary facial dermal filler injections with HA-based fillers within&#xD;
             12 months, porcine-based collagen fillers within 24 months prior to screening&#xD;
&#xD;
          -  have mid-face volume deficit due to congenital defect, trauma, abnormalities in&#xD;
             adipose tissue related to immune-mediated diseases&#xD;
&#xD;
          -  have history of anaphylaxis, multiple severe allergies, or allergy to lidocaine, HA&#xD;
             products, or Streptococcal protein&#xD;
&#xD;
          -  have history of bleeding disorder&#xD;
&#xD;
          -  have a tendency to develop hypertrophic scarring or keloid&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Investigator</last_name>
    <role>Principal Investigator</role>
    <affiliation>LG Chem Investigational site 01</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>LG Chem investigational site 01</name>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 3, 2021</study_first_submitted>
  <study_first_submitted_qc>March 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 5, 2021</study_first_posted>
  <last_update_submitted>November 11, 2021</last_update_submitted>
  <last_update_submitted_qc>November 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

